Comments
Hyderabad Aurobindo Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for Unit XIV located at Bonangi Village, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District, Andhra Pradesh.
The U.S. regulator conducted an inspection of unit XIV from May 15 to 19, 2023. “The Unit has now received the Establishment Inspection Report classifying the facility as “Voluntary action indicated” (VAI),’‘ the Hyderabad-based company informed the BSE on Monday.
The exact details of VAI have not been disclosed.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.